Manufacturing Compliance Updates In Brief From US FDA And EU
Executive Summary
Many of the six drug GMP warning letters the US FDA has issued since late March targeted lax testing practices, particularly at OTC firms abroad. Two EU GMP non-compliance notices highlighted data integrity shortcomings in India. FDA also posted a couple of Form 483 reports and added four facilities to its GMP import alert.
You may also be interested in...
US FDA Warns Indoco To Delve Further Into Manufacturing Deviation
On paper, the tablet press was in control. In reality, it was not. What did that mean for the company? A lot more than it appeared to realize.
Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants
Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.
FDA To Hanbul Cosmetics: You’re Marketing Noncompliant Drugs
The agency’s warning letter cites the Korean firm, whose offering includes sunscreen and skin-whitening products, for violations of drug CGMP regulations. Problems identified during a recent inspection include microbiological testing failures and questions about equipment quality.